Clinical Trial Update: Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating rivastigmine transdermal patch for cognitive impairment after traumatic brain injury has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Traumatic Brain Injury

Drugs mentioned

• Exelon Patch (rivastigmine transdermal patch)

Snippet

Sponsor: VA Office of Research and Development | Conditions: Traumatic Brain Injury, Cognitive Impairment | Phase 3 | Status: COMPLETED | Results posted: 2017-07-25